The buy side is looking quite sad, worst it has been for quite a while. Does it just mean everyone has shut up shop or has the change in direction and conversion from being an "oncology company targeting myc" to whatever the latest title is killed interest? What are we now, pivoting platforms or something? I still think it is probably best path but at the same time we discovered endosomal escape trap while working with Janssens and it wasnt' enough to keep them so will it be enough to attract new. I guess it was enough to attract an ex Janssen exec to the board so who knows, but last agm seemed to be all about setting up directors salary packages to be bullet proof regardless of outcomes. Would hate to see so drop again from these levels as it finally looked like we'd broken out.
Happy Christmas and lucky New Year to all holders. Hopefully next year is our time.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)